Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
61 hedge funds and large institutions have $57.1M invested in Concert Pharmaceuticals, Inc. in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 21 increasing their positions, 27 reducing their positions, and 18 closing their positions.
41% more call options, than puts
Call options by funds: $100K | Put options by funds: $71K
22% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 27
23% less funds holding
Funds holding: 79 → 61 (-18)
26% less capital invested
Capital invested by funds: $77M → $57.1M (-$19.9M)
94% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$346K |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$332K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$307K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$191K |
| 5 |
BlackRock
New York
|
+$175K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$861K |
| 2 |
Millennium Management
New York
|
-$538K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$482K |
| 4 |
Morgan Stanley
New York
|
-$478K |
| 5 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
-$348K |
CNCE Hedge Fund Activity: Q3 2021 in Review
61 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q3 2021, worth a combined $57.1M — down 26% from $77M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of CNCE and 1 opened new positions — a net loss of 17 holders — while 27 trimmed existing stakes and 21 added.
The largest buyer was GSA Capital Partners, adding an estimated $346K. The largest seller was Renaissance Technologies, cutting an estimated $861K.
- 61 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q3 2021, down from 79 in Q2 2021.
- Funds reported $57.1M of Concert Pharmaceuticals, Inc. stock for Q3 2021, down 26% quarter-over-quarter.
- 1 fund opened new Concert Pharmaceuticals, Inc. positions in Q3 2021 and 18 closed out, a net change of -17 holders.
- The largest Concert Pharmaceuticals, Inc. buyer in Q3 2021 was GSA Capital Partners, an estimated $346K added.
- The largest Concert Pharmaceuticals, Inc. seller in Q3 2021 was Renaissance Technologies, an estimated $861K sold.
Based on aggregated 13F filings for Q3 2021.